Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia (Q34495550)

2 August 2017

title

Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia (English)

1 reference

2 August 2017

0 references

Changyu Pan

1

1 reference

2 August 2017

Hyung Joon Yoo

series ordinal

2

1 reference

2 August 2017

Low-Tone Ho

series ordinal

3

1 reference

2 August 2017

publication date

29 December 2010

1 reference

2 August 2017

1 reference

2 August 2017

volume

2011

1 reference

2 August 2017

page(s)

957268

1 reference

Creative Commons Attribution 3.0 Unported

2 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high ant

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

A critical review of the cannabinoid receptor as a drug target for obesity management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Obesity in China: causes and solutions.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

The endocannabinoid system and gut-brain signalling.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Prevalence of obesity in Taiwan

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Prevalence of obesity in Korea

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

A novel pathway to the manifestations of metabolic syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Overweight and obesity in China

6 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

Body mass index and cancer risk in Korean men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

BMI and metabolic disorders in South Korean adults: 1998 Korea National Health and Nutrition Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3021887

Overweight and Obesity BMI Cut-offs and Their Relation to Metabolic Disorders in Koreans/Asians

27 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F957268

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

21 January 2018

1 reference

12 December 2020

Techniques for the measurement of visceral fat: a practical guide

1 reference

12 December 2020

Incidence of hypertension in individuals with abdominal obesity in a rural Japanese population: the Tanno and Sobetsu study

1 reference

12 December 2020

Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs

1 reference

12 December 2020

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/957268

1 reference

2 August 2017

1 reference

2 August 2017

1 reference